» Articles » PMID: 27497531

Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy

Abstract

Analysis of the clinical characteristics of hematopoietic stem cell transplant (HSCT) donors has proven beneficial for identifying cases of heritable hematopoietic disorders. This study examines poor peripheral blood hematopoietic stem cell mobilization after granulocyte colony-stimulating factor administration among 328 donors as a potential marker for suspected familial predisposition to myeloid malignancies. Here, we present data comparing the clinical characteristics of poor-mobilizing versus nonpoor-mobilizing donors and the results of panel-based sequencing of hematopoietic genes in poor-mobilizing donors. From this analysis, we identified a novel case of a donor-derived myelodysplastic syndrome in an HSCT recipient that is consistent with clonal evolution of TET2-mutated clonal hematopoiesis of indeterminate potential (CHIP) within the donor. This study demonstrates the potential risk of using hematopoietic stem cells from a donor with CHIP and raises the question of whether there should be increased screening measures to identify such donors.

Citing Articles

Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis.

Xie Y, Kazakova V, Weeks L, Gerber J, Tai J, Zhang T Bone Marrow Transplant. 2024; 59(11):1585-1593.

PMID: 39183321 PMC: 11531373. DOI: 10.1038/s41409-024-02403-2.


Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Banaszak L, Cabral P, Smith-Simmer K, Hassan A, Brunner M, Fallon M JCO Precis Oncol. 2024; 8:e2300518.

PMID: 38848520 PMC: 11234342. DOI: 10.1200/PO.23.00518.


Genomic testing for germline predisposition to hematologic malignancies.

Hwang S Blood Res. 2024; 59(1):12.

PMID: 38485837 PMC: 10923764. DOI: 10.1007/s44313-024-00012-y.


Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.

Williams L, Williams K, Gillis N, Bolton K, Damm F, Deuitch N Transplant Cell Ther. 2023; 30(3):255-267.

PMID: 37913908 PMC: 10947964. DOI: 10.1016/j.jtct.2023.10.018.


Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up.

Kim K, Kim T, Novitzky-Basso I, Lee H, Yoo Y, Ahn J Haematologica. 2023; 108(7):1817-1826.

PMID: 36727396 PMC: 10316278. DOI: 10.3324/haematol.2022.281806.


References
1.
Zhang M, Keel S, Walsh T, Lee M, Gulsuner S, Watts A . Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica. 2014; 100(1):42-8. PMC: 4281311. DOI: 10.3324/haematol.2014.113456. View

2.
Fogarty P, Yamaguchi H, Wiestner A, Baerlocher G, Sloand E, Zeng W . Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003; 362(9396):1628-30. DOI: 10.1016/S0140-6736(03)14797-6. View

3.
Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

4.
Vulliamy T, Walne A, Baskaradas A, Mason P, Marrone A, Dokal I . Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis. 2005; 34(3):257-63. DOI: 10.1016/j.bcmd.2004.12.008. View

5.
Olnes M, Poon A, Miranda S, Pfannes L, Tucker Z, Loeliger K . Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors. Transfusion. 2011; 52(3):537-41. PMC: 3235244. DOI: 10.1111/j.1537-2995.2011.03313.x. View